The UK’s Medicines and
Healthcare Products Regulatory
Agency (MHRA) has said
domperidone should not be used
by people with serious underlying
heart conditions.
The organisation advised the
treatment should only be used for
nausea relief at the lowest possible
dose, with adults taking no more
than three 10mg tablets a day.
This followed an EMA review of
the drug, which found that people
who took it might have a “small
increased risk of potentially life
threatening effects on the heart”,
the MHRA said.
The Therapeutic Goods
Administration (TGA) was reviewing
domperidone (Motilium) and
cardiac events, and the MHRA
advice would be considered in this
review, a spokesperson for the
Department of Health said.
For more, CLICK HERE.The above article was sent to subscribers in Pharmacy Daily's issue from 29 Apr 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Apr 14
PEAK pharmacy bodies are calling on the Australian Government to extend the new Commonwealth Prac Payment to pharmacy students, citing the challenges of “placement poverty” in unpaid practical placements.
AFT Pharmaceuticals is set to develop a topical treatment for keloid and hypertrophic scarring in partnership with NZ’s Massey Ventures, the commercialisation arm of Massey University, and the Gillies McIndoe Research Institute.
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.